US20070264341A1 - Process of preparing microspheres for sustained release having improved dispersibility and syringeability - Google Patents

Process of preparing microspheres for sustained release having improved dispersibility and syringeability Download PDF

Info

Publication number
US20070264341A1
US20070264341A1 US11/511,951 US51195106A US2007264341A1 US 20070264341 A1 US20070264341 A1 US 20070264341A1 US 51195106 A US51195106 A US 51195106A US 2007264341 A1 US2007264341 A1 US 2007264341A1
Authority
US
United States
Prior art keywords
microspheres
drug
sustained release
polyvinyl alcohol
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/511,951
Other languages
English (en)
Inventor
Hee-Yong Lee
Jung-Soo Kim
Eun-Ho Shin
Seong-Kyu Kim
Eun-Young Soel
Mi-Jin Baek
Mi-Young Baek
Yeon-Jin Chae
Ho-Il Choi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daewoong Pharmaceutical Co Ltd
Peptron Inc
Original Assignee
Daewoong Pharmaceutical Co Ltd
Peptron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd, Peptron Inc filed Critical Daewoong Pharmaceutical Co Ltd
Assigned to DAEWOONG PHARMACEUTICAL CO., LTD. reassignment DAEWOONG PHARMACEUTICAL CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAEK, MI-JIN, BAEK, MI-YOUNG, CHAE, YEON-JIN, CHOI, HO-IL, KIM, JUNG-SOO, KIM, SEONG-KYU, LEE, HEE-YONG, SEOL, EUN-YOUNG, SHIN, EUN-HO
Assigned to PEPTRON CO., LTD. reassignment PEPTRON CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAEK, MI-JIN, BAEK, MI-YOUNG, CHAE, YEON-JIN, CHOI, HO-IL, KIM, JUNG-SOO, KIM, SEONG-KYU, LEE, HEE-YONG, SEOL, EUN-YOUNG, SHIN, EUN-HO
Publication of US20070264341A1 publication Critical patent/US20070264341A1/en
Assigned to DAEWOONG PHARMACEUTICAL CO., LTD. reassignment DAEWOONG PHARMACEUTICAL CO., LTD. CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE SHOULD BE: "DAEWOONG PHARMACEUTICAL CO., LTD." PREVIOUSLY RECORDED ON REEL 019225 FRAME 0473. ASSIGNOR(S) HEREBY CONFIRMS THE THE ORIGINAL COVER SHEET MAILED APRIL 20, 2007 CORRECTLY LISTED "DAEWOONG PHARMACEUTICAL CO., LTD." AS THE ASSIGNEE.. Assignors: BAEK, MI-JIN, BAEK, MI-YOUNG, CHAE, YEON-JIN, CHOI, HO-IL, KIM, JUNG-SOO, KIM, SEONG-KYU, LEE, HEE-YONG, SEOL, EUN-YOUNG, SHIN, EUN-HO
Priority to US12/429,523 priority Critical patent/US9877922B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a process of preparing sustained release microspheres comprising a biodegradable polymer as a carrier and a drug.
  • Such microspheres are an injectable sustained-release formulation, which enables the sustained and uniform release of a drug so as to maintain its biological activity in the body upon subcutaneous or intramuscular injection.
  • Phase separation encapsulation is a process for preparing microspheres in which a biodegradable polymer is dissolved in an excessive amount of an organic solvent, such as methylene chloride, and a drug dissolved in a small amount of water is added to the polymer solution with stirring. Silicon oil is then added to the polymer-drug mixture at a constant rate to form embryonic microspheres, and an excessive amount of a non-solvent, such as trichlorofluoromethane, is added to the solution to extract the organic solvent from the embryonic microspheres. The solidified microspheres are recovered by filtration, and dried under pressure.
  • the phase separation method is problematic as follows.
  • the toxic solvent such as methylenechloride
  • the residual solvent reduces the stability of formulations, and may also be detrimental to health when administered to the body.
  • non-solvent such as freon, hexane, heptane, cyclohexane, and trichlorofluoromethane
  • This method is a process for preparing microspheres in which a mixture of a biodegradable polymer and a drug is melt-extruded through an extruder at a high temperature and pulverized at a low temperature.
  • the biodegradable polymer-drug mixture may be obtained by homogeneously mixing a polymer and a drug in a solvent, such as methylene chloride, with an agitator, and removing the organic solvent using a rotary evaporator or a vacuum dryer, or by cryo-milling at a low temperature and sieving each powder and blending the two fine powders.
  • microsphere preparation does not exclude the possibility of an interaction between the polymer and the drug and denaturation of the drug due to high temperature and high pressure upon melt-extrusion, and denaturation of the drug due to heat locally generated during cryopulverization. This method is also difficult to use to make microspheres having a uniform size, which are thus easy to inject.
  • the two methods for preparing microspheres in addition to the problems of residual solvent, difficulty in mass production and drug denaturation, have another disadvantage in that a biodegradable polymer used for the sustainable release of a drug is non-hydrophilic and thus poorly dispersible in an aqueous suspension for injection.
  • Water-in-oil-in-water (w/o/w) double emulsion evaporation has commonly been applied to encapsulate hydrophilic drugs, such as peptides or proteins, into polymeric microspheres.
  • hydrophilic drugs such as peptides or proteins
  • a hydrophilic drug is dissolved in water, and this aqueous phase is dispersed in an organic phase containing a biodegradable polymer to yield a primary emulsion (water in oil).
  • This primary emulsion is again dispersed in a secondary aqueous phase containing an emulsifier.
  • Single emulsion evaporation (oil in water (o/w)) has been commonly used in the encapsulation of lipophilic drugs.
  • a drug and a biodegradable polymer are co-dissolved in a mixture of suitable organic solvents (e.g., methanol and methylene chloride), and the resulting solution is dispersed in an aqueous phase.
  • suitable organic solvents e.g., methanol and methylene chloride
  • the polymer decreases in solubility and is thus solidified to form microspheres.
  • the technically important factor is the encapsulation efficiency of bioactive drugs.
  • the single emulsion evaporation method also can enhance drug encapsulation by suitably increasing the concentration of a biodegradable polymer (PLGA) dissolved in an organic solvent phase.
  • PLGA biodegradable polymer
  • microspheres prepared by double emulsion evaporation are more porous than those prepared by single emulsion evaporation, and thus have increased surface areas, leading to a relatively high initial release rate of a drug.
  • the single and double emulsion evaporation methods for preparing microspheres like the phase separation method, have the following disadvantages: difficulty in the removal of an organic solvent used for dissolving a biodegradable polymer, difficulty in mass production procedures due to changes in solvent removal rate, allergic reactions to gelatin used for increasing the viscosity of a primary emulsion, the possibility of a drug becoming denatured and losing its activity due to strong shearing force applied for making small microspheres during primary emulsion preparation, limited drug encapsulation, and the like.
  • the spray drying method has also been used for preparing finely atomized particles.
  • a solution of a material to be dried, or a suspension or emulsion in which a biodegradable polymer and a drug are homogenously dissolved is supplied to a nozzle, sprayed through the nozzle, and exposed to heated air to evaporate the solvent used.
  • the drug release rates of prepared microspheres greatly depend on the composition or content of a biodegradable polymer, the type or content of an additive, the composition of a solvent, and the like.
  • the parameters including the type of a spray nozzle through which a spray solution is sprayed (for example, a type that atomizes droplets using compressed air, a type that atomizes droplets using centrifugal force when a spray solution flows into a disc rotating at a high speed, a type that atomizes droplets using ultrasonic waves generated when a vibrator vibrates, etc.), supply rate of a spray solution, and temperature, supplied amount and supply rate of dry air.
  • the spray drying method unlike other methods for preparing sustained release microspheres, is advantageous in that it provides a continuous process, which facilitates microsphere production and thus conversion from small-scale to large-scale production.
  • the spray drying method has the advantage of permitting large-scale production of microspheres, it has disadvantages as follows.
  • the solvent used is not sufficiently removed merely by spray drying.
  • the residual solvent causes a problem in the stability of the biodegradable polymer upon long-term storage, leading to changes in drug release profiles of microspheres.
  • Another disadvantage of this method is that since biodegradable polymers used for drug encapsulation are mostly non-hydrophilic, microspheres prepared are not suspended well and are thus difficult to accurately administer.
  • the present inventors intended to provide a process for preparing bioactive drug-loaded biodegradable polymer microspheres, which are easy for mass production, by solving the aforementioned problems.
  • microspheres which are obtained by spray drying a solution, suspension or emulsion containing a biodegradable polymer, a drug and a solvent, are suspended in an aqueous solution containing polyvinyl alcohol to remove the residual solvent, the microspheres have improved suspendability and syringeability and high drug encapsulation efficiency with no residual toxic solvent, thereby leading to the present invention.
  • FIGS. 1 a and 1 b show the dispersion/withdrawal rates and syringeability of microspheres prepared in Preparation Example 1 according to the present invention in an aqueous solution, wherein, after a test was carried out according to the method described in Test Example 1, the withdrawal rates of microspheres in each tube ( FIG. 1 a ) and the deviation in each tube for the mean withdrawal rate ( FIG. 1 b ) were measured;
  • the present invention relates to a process of preparing sustained release microspheres, in which a solution, suspension or emulsion containing a biodegradable polymer, a drug and a solvent is spray dried, and microspheres thus obtained are dispersed in an aqueous solution containing polyvinyl alcohol, thereby more easily removing residual solvent and improving suspendability of the microspheres upon administration.
  • the present invention relates to a process of preparing sustained release microspheres having high drug encapsulation efficiency, almost no residual solvent, and improved suspendability by dissolving and spray drying a biodegradable polymer and a drug, suspending microspheres thus obtained in an aqueous solution in which polyvinyl alcohol is dissolved, and recovering, washing and freeze drying the microspheres.
  • the present invention provides a process of preparing sustained release microspheres, comprising spraying a solution, suspension or emulsion containing a biodegradable polymer, a drug and a solvent into a dry chamber and drying it using dry air to remove the solvent; and dispersing spray-dried microspheres in an aqueous solution containing polyvinyl alcohol to remove the residual solvent and improve dispersibility of the microspheres.
  • biodegradable polymer refers to a polymer that slowly degrades when administered to the body, and is thus not harmful to the body.
  • examples of such polymers include polylactide (PLA), polyglycolide (PGA) and their copolymer, poly(lactide-co-glycolide) (PLGA), polyorthoester, polyanhydride, polyhydroxybutyric acid, polycaprolactone, polyalkylcarbonate, and derivatives thereof.
  • drug includes peptides having biological activities, such as anticancer agents, antibiotics, antipyretics, analgesics, anti-inflammatory agents, antitussive expectorants, sedatives, antiulcer agents, antidepressants, antiallergenic agents, antidiabetic agents, antihyperlipidemic agents, antituberculous agents, hormonal agents, bone metabolic agents, immunoinhibitors, angiogenesis inhibitors, contraceptives, and vitamin-like agents.
  • biologically active peptide or protein drugs are preferred.
  • oligopeptides having biological activities include insulin, somatostatin and derivatives thereof, growth hormone, prolactin, adrenocorticotropic hormone, melanocyte-stimulating hormone, thyrotropin-releasing hormone and salts and derivatives thereof, thyroid-stimulating hormone, luteinizing hormone, follicle-stimulating hormone, vasopressin and derivatives thereof, oxytocin, calcitonin, parathyroid hormone, glucagon, gastrin, secretin, pancreozymin, cholecystokinin, angiotensin, human placental lactogen, human chorionic gonadotropin, and enkephalin and derivatives thereof.
  • polypeptides include endorphin, interferon ( ⁇ -type, ⁇ -type, ⁇ -type), interleukin, tuftsin, thymopoietin, thymosin, thymostimulin, thymic humoral factor (THF), serum thymic factor and derivatives thereof, tumor necrosis factor, colony stimulating factor (CSF), motilin, dynorphin, bombesin, neurotensin, bradykinin, caerulein, urokinase, asparaginase, kallikrein, substance P, nerve growth factor, blood coagulation factor VIII and IX, lysozyme, polymyxin B, colistin, gramicidin, bacitracin, protein synthesis-stimulating peptide, vasoactive intestinal polypeptide, platelet-derived growth factor, growth hormone-releasing factor, bone morphogenetic protein, epidermal growth factor, and erythropoietin.
  • the aqueous solution containing polyvinyl alcohol is used to more effectively remove the residual solvent inside microspheres immediately after spray drying and to disperse microspheres well in an injection solution upon administration.
  • This aqueous solution is removed through an additional washing step, and finally remains in microspheres at an amount less than 1%.
  • the removal speed of residual solvent may be controlled by altering the temperature of the suspension. Using this feature, upon small-scale production, the residual solvent may be removed within a short time at room or ambient temperature. Upon large-scale production, the suspension is maintained at low temperature to remove the residual solvent at a slow speed, thereby preventing deterioration of products due to extended handling time of large quantities of products.
  • the content of polyvinyl alcohol in the aqueous solution is preferably 0.01-20% (w/v), and more preferably 0.05-10% (w/v).
  • Polyvinyl alcohol has a molecular weight of 3,000 to 300,000, preferably 5,000 to 100,000, and has a hydration rate of 75% to 95%.
  • the amount of polyvinyl alcohol remaining on the surface of microspheres is preferably 0.02-1% (w/v), and more preferably 0.05-0.5% (w/v).
  • solvent refers to a material that is able to dissolve a biodegradable polymer and/or a drug.
  • An appropriate solvent may be selected by those having ordinary skill in the art according to the type of biodegradable polymer. Glacial acetic acid is preferred.
  • the present invention includes a step of dispersing microspheres in an aqueous solution of polyvinyl alcohol to improve the dispersibility of microspheres.
  • the dispersal step is carried out for about one minute or longer to achieve maximal effects.
  • the preferred dispersal time is 5 min or longer.
  • This spray drying method has advantages including easy mass production, low residual solvent, high drug encapsulation efficiency, and ideal drug release profiles, but has drawbacks including difficult dispersion and suspension of sustained release microspheres obtained by spray drying in an injection solution due to non-hydrophilicity of a polymer contained in the microspheres, and requirement of an additional step for removing the residual solvent to ensure the stability of microspheres upon long-term storage.
  • the present inventors intended to solve these disadvantages in the present invention.
  • a conventional method of preparing microspheres by spray-drying using two nozzles is disclosed in U.S. Pat. No. 5,622,657.
  • the cited invention provides a method of coating drug-loaded polymeric microspheres with an aggregation-preventing agent using two or more nozzles, in which a polymer solution containing a biologically active substance and an aqueous solution of an agent for preventing aggregation of microparticles are sprayed separately from different nozzles at the same time.
  • a similar method is disclosed in Korean Pat. No.
  • the method being characterized by spraying a dispersion in which a water-soluble dispersing agent is dissolved in the direction opposite to the spraying direction of a biodegradable polymer solution containing an active ingredient and the flow direction of dry air in order to coat a portion or all of sustained release microparticles with the water-soluble dispersing agent.
  • the cited inventions intended to prevent microspheres from aggregating by spraying an aqueous solution for preventing microsphere aggregation immediately after microspheres are formed using spray drying, but there are following disadvantages. Since microspheres are coated with an aggregation-preventing agent immediately after being spray dried, a toxic solvent used for dissolving a polymer for preparing microspheres remains in microspheres in large quantities.
  • aggregation-preventing agents used in the cited inventions such as hydroxypropylcellulose, carboxymethylcellulose, glycin, alanin, gelatin and collagen, do not improve the suspendability in an injection solution or the syringeability, resulting in non-uniform dosages.
  • a water-soluble dispersing agent such as hydroxypropylmethylcellulose, hydroxypropylcellulose, and polyvinyl alcohol
  • a drug to be contained in the resulting preparation in an amount of about 4 to 19 wt %
  • D. Ermis, A. Yuksel Preparation of spray-dried microspheres of indomethacin and examination of the effects of coating on dissolution rates, J. Microencapsulation, vol. 16, No. 3, 3,315-324(1999).
  • the water-soluble dispersing agents are used to enhance the solubility of poorly water-soluble drugs, thereby dissolving the drugs within several hours, and increase the fluidity of drug particles, thereby facilitating processing such as tabletting.
  • Polyvinyl alcohol has been registered as a material liable to induce cancer when parenterally administered to animals, and thus the residual amount thereof should be controlled (Carcinogenic Studies on Water-Soluble and Insoluble Macromolecules, Archives of Pathology, 67, 589-617, 1959).
  • the present inventors found that when polyvinyl alcohol, suspended in a polymer solution, is sprayed as described in the above literature, the content of polyvinyl alcohol, which is difficult to degrade in the body, increases, and the initial drug release greatly increases. Such a high initial drug release may cause side effects, and may lead to a reduced drug release duration, thereby not guaranteeing suitable therapeutic effects.
  • the present inventors prepared microspheres in which the residual solvent is additionally removed and which have improved syringeability, through a process comprising preparing microspheres using a spray drying method developed by the present inventors prior to the present invention, suspending the microspheres in an aqueous solution containing polyvinyl alcohol, and washing and recovering the microspheres.
  • the process of preparing biodegradable polymer microspheres containing a drug having biological activity comprises preparing microspheres by spray drying, suspending the microspheres thus obtained in an aqueous solution containing polyvinyl alcohol, and recovering, washing and drying the microspheres, allows further removal of the residual solvent and improves the suspendability of microspheres upon administration, thereby leading to accurate administration of drugs and effective treatment of diseases.
  • PLGA microspheres were prepared using a spray dryer (SODEVA, France) equipped with an ultrasonic nozzle (Sono-Tek, 120 kHz).
  • 50 g of RG503H and 2.5 g of leuprolelin acetate were homogeneously dissolved in 500 ml of glacial acetic acid (Yakuri Pure Chemicals, Japan). The solution was transported at a flow rate of 3 ml/min using a piston pump.
  • the transported solution was sprayed into the spray drier through an ultrasonic nozzle installed in an upper part of a sprayer, and dried with dry air at 200° C. Thereafter, microspheres recovered from a cyclone were taken in a certain volume, weighed precisely, added at a concentration of 50 mg/ml to an aqueous solution containing distilled water and 1% (w/v) of a dispersing agent, and suspended therein for one hour at room temperature using a magnetic agitator.
  • the suspension was passed through a vacuum filter. Microspheres thus collected were washed with distilled water two times and freeze-dried.
  • microspheres immediately after spray drying, which did not undergo a dispersal process, and microspheres that underwent a dispersal process in distilled water not containing a dispersing agent were found to decrease with respect to withdrawal rate and homogeneity when drawn into a syringe and injected from the syringe.
  • dispersing agents mentioned in the literature studies polyvinyl alcohol exhibited the highest withdrawal rate, followed by gelatin, human serum albumin and Tween 80.
  • FIG. 1 a shows the withdrawal rates and homogeneity of microspheres, which did not undergo a dispersal process or underwent a dispersal process using mannitol and polyvinyl alcohol as dispersing agents, when a microsphere suspension was drawn into a syringe and injected from the syringe into a tube.
  • FIG. 1 b shows the deviation in each tube for the mean withdrawal rate in a syringe when microspheres did not undergo a dispersal process or underwent a dispersal process using polyvinyl alcohol as a dispersing agent.
  • microspheres had the highest withdrawal rate and the best homogeneity when undergoing a dispersal process using polyvinyl alcohol.
  • PLGA microspheres were prepared using a spray dryer (SODEVA, France) equipped with an ultrasonic nozzle (Sono-Tek, 120 kHz).
  • 40 g of RG503H and 4 g of leuprolelin acetate were homogeneously dissolved in 400 ml of glacial acetic acid. The solution was sprayed into a spray drier through an ultrasonic nozzle at a flow rate of 3 ml/min, and dried with dry air at 200° C.
  • microspheres recovered from a cyclone were taken in a predetermined amount, added at a concentration of 50 mg/ml to an aqueous solution containing 1% (w/v) polyvinyl alcohol, and suspended therein for 1 min, 3 min, 5 min, 10 min, 1 hr, 3 hr and 6 hr at 25° C. using a magnetic agitator. The suspension was passed through a vacuum filter. Microspheres thus collected were washed with distilled water two times, and freeze-dried.
  • microspheres prepared in Preparation Example 2 were dispersed in an aqueous solution, and assessed for withdrawal rates into a syringe and syringeability. This test was performed according to the same method as in Test Example 1, and the results are given in Table 2, below.
  • Residual polyvinyl alcohol amounts according to dispersal time 1 min 3 min 5 min 10 min 1 hr 3 hr 6 hr Residual amount 0.02 0.04 0.05 0.07 0.12 0.22 0.38 (w/w)
  • PLGA microspheres were prepared using a spray dryer (SODEVA, France) equipped with an ultrasonic nozzle (Sono-Tek, 120 kHz).
  • To prepare a control microsphere formulation 1.8 g of RG503H and 0.2 g of leuprolelin acetate were homogeneously dissolved in 90 ml of glacial acetic acid. The solution was transported at a flow rate of 1.5 ml/min using a piston pump. The transported solution was sprayed into the spray drier through an ultrasonic nozzle installed at an upper part of a sprayer, and dried with dry air at 200° C.
  • microspheres recovered from a cyclone were taken in a predetermined amount, added at a concentration of 50 mg/ml to an aqueous solution containing 1% (w/v) polyvinyl alcohol as a dispersing agent, and suspended therein for 1 hr at room temperature using a magnetic agitator. The suspension was passed through a vacuum filter. Microspheres thus collected were washed with distilled water two times and freeze-dried.
  • a comparative microsphere formulation was prepared by spray drying microspheres and polyvinyl alcohol at the same time in order to compare the dispersal effect of co-spray dried polyvinyl alcohol with that in the control formulation.
  • 1.8 g of RG503H and 0.2 g of leuprolelin acetate were homogeneously dissolved in 90 ml of glacial acetic acid.
  • the solution was transported at a flow rate of 1.5 ml/min using a piston pump.
  • the transported solution was sprayed into the spray drier through an ultrasonic nozzle installed at an upper part of a sprayer, and dried with dry air at 200° C, thereby yielding a comparative formulation.
  • control and comparative microsphere formulations prepared as described above were individually dispersed in an aqueous solution, and assessed for withdrawal rates into a syringe and syringeability.
  • This assay was performed according to the same method as in Test Example 1, and final dry weights of microspheres in tubes were measured. The results are given in Table 4, below.
  • the residual polyvinyl alcohol amount of each microsphere formulation was determined according to the same method as in Test Example 3.
  • the comparative microsphere formulation not undergoing a suspending process had a high residual polyvinyl alcohol concentration, but exhibited decreased withdrawal rate and homogeneity when withdrawn, into a syringe and injected therefrom, and a high initial drug release rate.
  • Microspheres were prepared in and recovered from a cyclone according to the same method as in Preparation Example 2, and suspended in an aqueous solution of 1% polyvinyl alcohol at a concentration of 50 mg/ml. While the aqueous solution was maintained at 25° C., the removal rates of residual acetic acid were measured at given time points. The concentrations of residual acetic acid in microspheres were determined as follows. Microspheres were dissolved in methylene chloride (Junsei, 34355-0350), supplemented with an aqueous solution of 0.07% phosphoric acid (Sigma, P-6560), and vigorously mixed therewith. The mixture was centrifuged to separate a layer of the aqueous phosphoric acid solution.
  • This layer was recovered and assessed for the amount of acetic acid using HPLC.
  • HPLC was carried out using a C18 column (5 ⁇ m, 4.6 ⁇ 250 mm, 120 ⁇ ). A mixture of 5-50% linear gradient of methanol (J. T. Baker, AH230-4) and 0.07% phosphate buffer (pH 3.0) was used as a mobile phase having a flow rate of 1.2 ml/min. Acetic acid was detected at 210 nm (UV), and the results are given in Table 5, below. The residual acetic acid content immediately after microspheres were prepared was 0.8 wt %.
  • the residual solvent removal rates gradually increased with increasing time of suspension of microspheres in an aqueous solution of polyvinyl alcohol to remove the residual solvent.
  • the final residual solvent was maintained at less than 0.1 wt %.
  • bovine serum albumin (Sigma, A-7638) was dissolved in distilled water, and homogeneously mixed with a solution prepared by dissolving 9.5 g of RG502H in 95 ml of methylene chloride, thereby yielding a W/O type emulsion. While the emulsion was maintained in an emulsion state using an agitator, it was supplied to a spray drier (Buchi-191) at a flow rate of 3 ml/min. Compressed air was supplied to a two-fluid nozzle at a flow rate of 450 NL/h to dry sprayed atomized droplets using dry air at 80° C.
  • BSA bovine serum albumin
  • the recovered microspheres were suspended for 3 hrs in an aqueous solution of 1% polyvinyl alcohol at a concentration of 50 mg/ml with agitation using a magnetic agitator, washed with distilled water, and freeze-dried.
  • the microspheres thus prepared had a mean particle size of 5.2 ⁇ m, and the amount of polyvinyl alcohol remaining on the surface of the microspheres was 0.93% (w/w).
  • the recovered microspheres were suspended for 3 hrs in an aqueous solution of 1% polyvinyl alcohol at a concentration of 50 mg/ml with agitation using a magnetic agitator, washed with distilled water, and freeze-dried.
  • the microspheres thus prepared had a mean particle size of 5.8 ⁇ m, and the amount of polyvinyl alcohol remaining on the surface of the microspheres was 0.85% (w/w).
  • 0.5 g of leuprolelin acetate and 9.5 g of R202H were dissolved in 95 ml of glacial acetic acid.
  • the solution was supplied to a spray drier (SODEVA, France) at a flow rate of 3 ml/min, sprayed into a dry chamber using an ultrasonic nozzle (Sono-Tek, 60 kHz), and dried using dry air at 200° C.
  • the recovered microspheres were suspended for 3 hrs in an aqueous solution of 1% polyvinyl alcohol at a concentration of 50 mg/ml with agitation using a magnetic agitator, washed with distilled water, and freeze-dried.
  • the microspheres thus prepared had a mean particle size of 32.6 ⁇ m, and the amount of polyvinyl alcohol remaining on the surface of the microspheres was 0.11% (w/w).
  • octreotide acetate and 9.3 g of RG502H were dissolved in 186 ml of glacial acetic acid.
  • the solution was supplied to a spray drier (SODEVA, France) at a flow rate of 3 ml/min, sprayed into a dry chamber using an ultrasonic nozzle (Sono-Tek, 120 kHz), and dried using dry air at 200° C.
  • the recovered microspheres were suspended for 1 hr in an aqueous solution of 1% polyvinyl alcohol at a concentration of 50 mg/ml with agitation using a magnetic agitator, washed with distilled water, and freeze-dried.
  • Rats were challenged with the microspheres at a dosage of 100 ⁇ g/kg (based on leuprolelin acetate) 28, 56 and 84 days after drug administration in order to evaluate the sustained release of the drug from the microspheres, and blood samples were collected before drug administration and 3 and 24 hrs after drug administration. Secondary drug administration was carried out 90 days after the primary drug administration, and blood samples were collected as described in the primary drug administration. The collected blood samples were placed into 1.5-ml Eppendorff tubes, and centrifuged for 10 min at 4° C. and 12,000 rpm. The-obtained sera were stored at ⁇ 20° C.
  • Serum testosterone levels were measured using a radio-immunoassay (RIA) Kit (DSL-10-4000, Diagnostic System Laboratories, Inc., Webster, Tex., USA), and the results are given in FIG. 2 .
  • Blood samples were collected from tail veins before drug administration and 6 hrs and 1, 4, 7, 13, 21 and 31 days after drug administration.
  • the collected blood samples were placed into 1.5-ml Eppendorff tubes, and centrifuged for 10 min at 4° C. and 12,000 rpm.
  • the obtained sera were stored at ⁇ 20° C.
  • Serum octreotide concentrations were measured using an enzyme immunoassay (EIA) kit (Bachem, S-1275, Peninsula Laboratories Inc., USA). The results are given in FIG. 3 . As shown in FIG. 3 , the octreotide drug was found to be continuously released for a period of more than two weeks.
  • EIA enzyme immunoassay
  • the process of preparing microspheres according to the present invention allows the preparation of sustained release microspheres not having the problems of conventional preparation methods of sustained release microspheres, including toxicity due to residual solvent and poor syringeability.
  • the microspheres prepared according to the present invention release an effective concentration of a drug in a sustained manner for a predetermined period when administered to the body, prevent rapid initial drug release, and reduce the required administration frequency of a drug.
  • the present microspheres are useful in the treatment of diseases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
US11/511,951 2006-05-11 2006-08-29 Process of preparing microspheres for sustained release having improved dispersibility and syringeability Abandoned US20070264341A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/429,523 US9877922B2 (en) 2006-05-11 2009-04-24 Process of preparing microspheres for sustained release having improved dispersibility and syringeability

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020060042462A KR100722607B1 (ko) 2006-05-11 2006-05-11 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법
KR10-2006-0042462 2006-05-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/429,523 Continuation-In-Part US9877922B2 (en) 2006-05-11 2009-04-24 Process of preparing microspheres for sustained release having improved dispersibility and syringeability

Publications (1)

Publication Number Publication Date
US20070264341A1 true US20070264341A1 (en) 2007-11-15

Family

ID=38278452

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/511,951 Abandoned US20070264341A1 (en) 2006-05-11 2006-08-29 Process of preparing microspheres for sustained release having improved dispersibility and syringeability
US12/429,523 Active 2028-02-11 US9877922B2 (en) 2006-05-11 2009-04-24 Process of preparing microspheres for sustained release having improved dispersibility and syringeability

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/429,523 Active 2028-02-11 US9877922B2 (en) 2006-05-11 2009-04-24 Process of preparing microspheres for sustained release having improved dispersibility and syringeability

Country Status (10)

Country Link
US (2) US20070264341A1 (es)
EP (1) EP2015737B1 (es)
JP (1) JP5191480B2 (es)
KR (1) KR100722607B1 (es)
CN (1) CN101528206B (es)
BR (1) BRPI0712080B1 (es)
ES (1) ES2571855T3 (es)
MX (1) MX2008014456A (es)
RU (1) RU2403017C2 (es)
WO (1) WO2007133020A1 (es)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090269414A1 (en) * 2006-05-11 2009-10-29 Peptron Co., Ltd. Process of preparing microspheres for sustained release having improved dispersibility and syringeability
US20090317478A1 (en) * 2008-06-19 2009-12-24 Korea Institute Of Science And Technology Method of preparing covered porous biodegradable polymer microspheres for sustained-release drug delivery and tissue regeneration
US20100086597A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for the sustained release of octreotide with a low initial burst
US9156016B2 (en) 2010-09-30 2015-10-13 Midatech Pharma (Wales) Limited Apparatus and method for making solid beads
US9259701B2 (en) 2010-09-30 2016-02-16 Q Chip Ltd. Method for making solid beads
US20180110832A1 (en) * 2015-04-20 2018-04-26 The Board Of Regents Of The University Of Texas Sy Stem Clec11a is a bone growth agent
EP3247337A4 (en) * 2015-01-20 2018-08-01 Hyalo Technologies, LLC Method of preparing microspheres
WO2021101140A1 (ko) * 2019-11-22 2021-05-27 주식회사 지씨에스 폴리-l-락틱산 필러와 히알루론산 필러 결합체를 함유하는 서방성 주사제제 및 그 제조방법
KR20210063266A (ko) * 2019-11-22 2021-06-01 주식회사 지씨에스 히알루론산-plla 필러 미세캡슐을 포함하는 필러 주사제제 및 이의 제조방법
CN113616588A (zh) * 2021-08-17 2021-11-09 爱尔眼科医院集团股份有限公司长沙爱尔眼科医院 一种含有罗格列酮Pd@ZIF-8纳米颗粒缓控释膜的制备方法及应用
CN113855848A (zh) * 2021-10-18 2021-12-31 四川大学 单分散硼酸交联聚乙烯醇栓塞微球及其制备方法
US11291636B2 (en) 2011-11-18 2022-04-05 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles
CN115297849A (zh) * 2020-03-16 2022-11-04 株式会社理光 用于生产颗粒的方法

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101005562B1 (ko) * 2008-05-01 2011-01-05 한국생명공학연구원 난용성 약물을 함유하는 균일한 크기의 고분자 나노입자제조방법
NZ596610A (en) * 2009-05-27 2014-04-30 Samyang Biopharmaceuticals A poorly soluble drug containing microsphere with improved bioavailability and method of preparing the same
EP2353588B1 (en) * 2010-01-21 2015-04-15 Agricultural Technology Research Institute A sustained release preparation of factor IX
US8865220B2 (en) * 2010-06-14 2014-10-21 Kaohsiung Medical University Method for controlled release of parathyroid hormone from encapsulated poly(lactic-glycolic)acid microspheres
KR101481859B1 (ko) * 2011-05-20 2015-01-14 에스케이케미칼주식회사 초기 약물 방출이 감소된 고분자 미립자의 제조방법 및 그 방법에 의해 제조된 고분자 미립자
BR102012011209A2 (pt) * 2012-05-11 2014-03-25 Bioactive Biomateriais Ltda Material tridimensional polimérico biodegradável e processo de preparo de material tridimensional polimérico biodegradável
US20140106001A1 (en) * 2012-10-15 2014-04-17 Commercial Marine Biology Institute, Llc Marine extract compositions and methods of use
KR101307729B1 (ko) * 2012-11-19 2013-09-11 에스케이케미칼주식회사 초기 약물 방출이 감소된 고분자 미립자를 포함하는 주사용 조성물 및 이의 제조방법
KR101334011B1 (ko) * 2012-11-19 2013-11-27 에스케이케미칼주식회사 아나스트로졸 함유 서방출형 고분자 미립구
BR112016005768B1 (pt) 2013-09-19 2021-09-21 Microvention, Inc Películas de polímero
JP6405369B2 (ja) 2013-09-19 2018-10-17 テルモ株式会社 ポリマー粒子
EP3065719A4 (en) 2013-11-08 2017-08-09 Terumo Corporation Polymer particles
CA2951905A1 (en) * 2014-06-12 2015-12-17 Orbis Biosciences, Inc. Extended-release drug delivery compositions
CN104399058A (zh) * 2014-10-30 2015-03-11 北京天晟泰丰医药科技有限公司 一种十肽微球的制备方法
KR101583351B1 (ko) * 2014-11-28 2016-01-07 동국제약 주식회사 초기 방출 억제 및 잔류용매 제거율을 향상시킨 서방출성 미립구 및 이의 제조방법
WO2016154592A1 (en) 2015-03-26 2016-09-29 Microvention, Inc. Embiolic particles
CN106546705B (zh) * 2015-09-21 2020-03-17 上海复旦张江生物医药股份有限公司 一种脂质体药物体外释放的测试方法
CN106546706B (zh) * 2015-09-21 2020-03-17 上海复旦张江生物医药股份有限公司 pH梯度主动载药法制备的脂质体药物的体外释放测试方法
KR102310696B1 (ko) 2016-09-28 2021-10-12 테루모 가부시키가이샤 색전 조성물
KR101900482B1 (ko) * 2017-01-17 2018-09-19 한국화학연구원 미립구형 서방출 주사제 및 그의 제조방법
CN107510600A (zh) * 2017-08-07 2017-12-26 苏州大学 一种制备药用固体微粒的设备及方法
KR102047983B1 (ko) * 2017-11-30 2019-11-22 주식회사 지투지바이오 안전성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법
CN111886031B (zh) * 2018-01-10 2022-10-14 G2G生物公司 含胶原蛋白肽的聚己内酯微球填充物及其制备方法
JP7092974B2 (ja) 2018-03-26 2022-06-29 株式会社リコー 樹脂微粒子の製造方法、及び樹脂微粒子の製造装置
US20220023217A1 (en) * 2018-12-17 2022-01-27 G2Gbio, Inc. Sustained-release injection comprising deslorelin, and preparation method therefor
CN109985585A (zh) * 2019-05-13 2019-07-09 苏州岸谷纳米技术有限公司 一种生物降解高分子微球的快速制备方法
KR102184198B1 (ko) * 2019-11-22 2020-11-30 주식회사 지씨에스 폴리-l-락틱산 필러와 히알루론산 필러 결합체 및 생체 활성물질을 함유하는 서방성 주사제제 및 그 제조방법

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4652441A (en) * 1983-11-04 1987-03-24 Takeda Chemical Industries, Ltd. Prolonged release microcapsule and its production
US4673595A (en) * 1984-10-17 1987-06-16 Debiopharm, S.A. Microencapsulation by phase separation of water-soluble medicaments
US4954298A (en) * 1985-02-07 1990-09-04 Takeda Chemical Industries, Ltd. Method for producing microcapsule
US5134122A (en) * 1989-07-28 1992-07-28 Debiopharm S.A. Method for preparing a pharmaceutical composition in the form of microparticles
US5192741A (en) * 1987-09-21 1993-03-09 Debiopharm S.A. Sustained and controlled release of water insoluble polypeptides
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
US5431348A (en) * 1992-08-21 1995-07-11 Debio Recherche Pharmaceutique Sa Ultracentrifugal disintegrator and its use for the cryocomminution of heat sensitive material
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
US5445832A (en) * 1991-07-22 1995-08-29 Debio Recherche Pharmaceutique S.A. Process for the preparation of microspheres made of a biodegradable polymeric material
US5480656A (en) * 1990-02-13 1996-01-02 Takeda Chemical Industries, Ltd. Prolonged release microcapsules
US5611971A (en) * 1992-08-07 1997-03-18 Takeda Chemical Industries, Ltd. Production of microcapsules of water-soluble drugs
US5622657A (en) * 1991-10-01 1997-04-22 Takeda Chemical Industries, Ltd. Prolonged release microparticle preparation and production of the same
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US6190700B1 (en) * 1995-12-15 2001-02-20 Takeda Chemical Industries, Ltd. Production of sustained-release preparation for injection
US20050042294A1 (en) * 2003-07-18 2005-02-24 Thanoo Bagavathikanun C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
US20050261195A1 (en) * 1999-06-30 2005-11-24 Takeda Pharmaceutical Company Limited Process for preparing LH-RH derivatives

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
YU48420B (sh) * 1991-03-25 1998-07-10 Hoechst Aktiengesellschaft Postupak za dobijanje biološki razgradljivih mikročestica sa dugotrajnim delovanjem
GB9423419D0 (en) * 1994-11-19 1995-01-11 Andaris Ltd Preparation of hollow microcapsules
KR970000219A (ko) * 1995-06-14 1997-01-21 김종국 약물의 다중막 미립구 및 그의 제조방법
AU1226901A (en) * 1999-10-22 2001-05-08 Amgen, Inc. Biodegradable microparticles with novel erythropoietin stimulating protein
WO2001078687A1 (en) * 2000-04-18 2001-10-25 Peptron Inc. Injectable sustained release pharmaceutical composition and processes for preparing the same
KR100392501B1 (ko) * 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
KR100566573B1 (ko) * 2002-04-13 2006-03-31 주식회사 펩트론 Ｌｈｒｈ 동족체를 함유하는 서방성 미립구의 제조방법
WO2004030659A1 (en) * 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
KR100466637B1 (ko) * 2003-06-26 2005-01-13 주식회사 펩트론 서방성 미립구의 혼합 제형을 연속한 단일 공정으로제조하는 방법
KR100453273B1 (ko) * 2003-09-04 2004-10-15 주식회사 펩트론 초음파 이중공급노즐을 이용한 서방성 미립구의 제조 방법
EP1742616B1 (en) * 2004-04-30 2014-10-01 Abraxis BioScience, LLC Sustained-release microspheres and methods of making and using same
KR100722607B1 (ko) * 2006-05-11 2007-05-28 주식회사 펩트론 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법

Patent Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US5476663A (en) * 1983-11-04 1995-12-19 Takeda Chemical Industries, Ltd. Prolonged release microcapsule
US4652441A (en) * 1983-11-04 1987-03-24 Takeda Chemical Industries, Ltd. Prolonged release microcapsule and its production
US4711782A (en) * 1983-11-04 1987-12-08 Takeda Chemical Industries, Ltd. Prolonged release microcapsules and their production
US5061492A (en) * 1983-11-04 1991-10-29 Takeda Chemical Industries, Ltd. Prolonged release microcapsule of a water-soluble drug
US5631020A (en) * 1983-11-04 1997-05-20 Takeda Chemical Industries, Ltd. Method for producing microcapsule
US5631021A (en) * 1983-11-04 1997-05-20 Takeda Chemical Industries, Ltd. Method for producing microcapsule
US4673595A (en) * 1984-10-17 1987-06-16 Debiopharm, S.A. Microencapsulation by phase separation of water-soluble medicaments
US4954298A (en) * 1985-02-07 1990-09-04 Takeda Chemical Industries, Ltd. Method for producing microcapsule
US5330767A (en) * 1985-02-07 1994-07-19 Takeda Chemical Industries, Ltd. Sustained release microcapsule
US5192741A (en) * 1987-09-21 1993-03-09 Debiopharm S.A. Sustained and controlled release of water insoluble polypeptides
US5776885A (en) * 1987-09-21 1998-07-07 Debio Recherche Pharmaceutique Sa Sustained and controlled release of water insoluble polypeptides
US5134122A (en) * 1989-07-28 1992-07-28 Debiopharm S.A. Method for preparing a pharmaceutical composition in the form of microparticles
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
US5480656A (en) * 1990-02-13 1996-01-02 Takeda Chemical Industries, Ltd. Prolonged release microcapsules
US5445832A (en) * 1991-07-22 1995-08-29 Debio Recherche Pharmaceutique S.A. Process for the preparation of microspheres made of a biodegradable polymeric material
US5622657A (en) * 1991-10-01 1997-04-22 Takeda Chemical Industries, Ltd. Prolonged release microparticle preparation and production of the same
US5611971A (en) * 1992-08-07 1997-03-18 Takeda Chemical Industries, Ltd. Production of microcapsules of water-soluble drugs
US5431348A (en) * 1992-08-21 1995-07-11 Debio Recherche Pharmaceutique Sa Ultracentrifugal disintegrator and its use for the cryocomminution of heat sensitive material
US6190700B1 (en) * 1995-12-15 2001-02-20 Takeda Chemical Industries, Ltd. Production of sustained-release preparation for injection
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US20050261195A1 (en) * 1999-06-30 2005-11-24 Takeda Pharmaceutical Company Limited Process for preparing LH-RH derivatives
US20050042294A1 (en) * 2003-07-18 2005-02-24 Thanoo Bagavathikanun C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9877922B2 (en) * 2006-05-11 2018-01-30 Peptron Co., Ltd. Process of preparing microspheres for sustained release having improved dispersibility and syringeability
US20090269414A1 (en) * 2006-05-11 2009-10-29 Peptron Co., Ltd. Process of preparing microspheres for sustained release having improved dispersibility and syringeability
US20090317478A1 (en) * 2008-06-19 2009-12-24 Korea Institute Of Science And Technology Method of preparing covered porous biodegradable polymer microspheres for sustained-release drug delivery and tissue regeneration
US8192655B2 (en) * 2008-06-19 2012-06-05 Korea Institute Of Science And Technology Method of preparing covered porous biodegradable polymer microspheres for sustained-release drug delivery and tissue regeneration
US20100086597A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for the sustained release of octreotide with a low initial burst
WO2010042432A1 (en) * 2008-10-06 2010-04-15 Oakwood Laboratories LLC Microspheres for the sustained release of octreotide with a low initial burst
US9259701B2 (en) 2010-09-30 2016-02-16 Q Chip Ltd. Method for making solid beads
US9156016B2 (en) 2010-09-30 2015-10-13 Midatech Pharma (Wales) Limited Apparatus and method for making solid beads
US11951216B2 (en) 2011-11-18 2024-04-09 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles
US11291636B2 (en) 2011-11-18 2022-04-05 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles
EP3247337A4 (en) * 2015-01-20 2018-08-01 Hyalo Technologies, LLC Method of preparing microspheres
US10149826B2 (en) 2015-01-20 2018-12-11 Hyalo Technologies, LLC Method of preparing microspheres
US11285190B2 (en) * 2015-04-20 2022-03-29 The Board Of Regents Of The University Of Texas System CLEC11a is a bone growth agent
US20180110832A1 (en) * 2015-04-20 2018-04-26 The Board Of Regents Of The University Of Texas Sy Stem Clec11a is a bone growth agent
US11890320B2 (en) 2015-04-20 2024-02-06 The Board Of Regents Of The University Of Texas System CLEC11A is a bone growth agent
KR20210063263A (ko) * 2019-11-22 2021-06-01 주식회사 지씨에스 히알루론산 및 폴리-l-락틱산 필러 결합체를 함유하는 주사제제 및 그 제조방법
KR20210063264A (ko) * 2019-11-22 2021-06-01 주식회사 지씨에스 감마선 조사 단계를 포함하는 필러 주사제제의 제조방법
KR20210063265A (ko) * 2019-11-22 2021-06-01 주식회사 지씨에스 가교 히알루론산과 plla 필러 결합체를 포함하는 필러 주사제제 및 이의 제조방법
KR102385223B1 (ko) 2019-11-22 2022-04-12 주식회사 지씨에스 감마선 조사 단계를 포함하는 필러 주사제제의 제조방법
KR102385287B1 (ko) 2019-11-22 2022-04-12 주식회사 지씨에스 히알루론산-plla 필러 미세캡슐을 포함하는 필러 주사제제 및 이의 제조방법
KR102385241B1 (ko) 2019-11-22 2022-04-12 주식회사 지씨에스 가교 히알루론산과 plla 필러 결합체를 포함하는 필러 주사제제 및 이의 제조방법
KR102385210B1 (ko) 2019-11-22 2022-04-12 주식회사 지씨에스 히알루론산 및 폴리-l-락틱산 필러 결합체를 함유하는 주사제제 및 그 제조방법
US11865225B2 (en) 2019-11-22 2024-01-09 Gcs Co., Ltd. Sustained release injectable formulation containing a poly L lactic acid filler and a hyaluronic acid filler conjugate and a method for preparing the same
KR20210063266A (ko) * 2019-11-22 2021-06-01 주식회사 지씨에스 히알루론산-plla 필러 미세캡슐을 포함하는 필러 주사제제 및 이의 제조방법
WO2021101140A1 (ko) * 2019-11-22 2021-05-27 주식회사 지씨에스 폴리-l-락틱산 필러와 히알루론산 필러 결합체를 함유하는 서방성 주사제제 및 그 제조방법
CN115297849A (zh) * 2020-03-16 2022-11-04 株式会社理光 用于生产颗粒的方法
CN113616588A (zh) * 2021-08-17 2021-11-09 爱尔眼科医院集团股份有限公司长沙爱尔眼科医院 一种含有罗格列酮Pd@ZIF-8纳米颗粒缓控释膜的制备方法及应用
CN113855848A (zh) * 2021-10-18 2021-12-31 四川大学 单分散硼酸交联聚乙烯醇栓塞微球及其制备方法

Also Published As

Publication number Publication date
ES2571855T3 (es) 2016-05-27
JP5191480B2 (ja) 2013-05-08
CN101528206B (zh) 2012-02-15
MX2008014456A (es) 2009-04-01
CN101528206A (zh) 2009-09-09
RU2403017C2 (ru) 2010-11-10
RU2008148817A (ru) 2010-06-20
US9877922B2 (en) 2018-01-30
EP2015737A4 (en) 2013-01-23
US20090269414A1 (en) 2009-10-29
BRPI0712080A2 (pt) 2012-01-17
BRPI0712080B1 (pt) 2021-09-14
KR100722607B1 (ko) 2007-05-28
JP2009536942A (ja) 2009-10-22
EP2015737B1 (en) 2016-03-23
WO2007133020A1 (en) 2007-11-22
EP2015737A1 (en) 2009-01-21

Similar Documents

Publication Publication Date Title
US9877922B2 (en) Process of preparing microspheres for sustained release having improved dispersibility and syringeability
EP0839525B1 (en) Sustained-release preparation
US8637077B2 (en) Sustained-release preparation
KR100297267B1 (ko) 미립자제제및그의제조법
EP0586238B1 (en) Method of producing sustained-release microcapsules
CN1055618C (zh) 缓释微胶囊的制备方法
EP0781548B1 (en) Production of sustained-release preparation for injection
CA2316159C (en) Prolonged release microcapsules
KR100259989B1 (ko) 서방성 마이크로캡슐 제제 및 그의 제조법
US7399486B2 (en) Method of preparing mixed formulation of sustained release microspheres by continuous one-step process
JP5160005B2 (ja) 徐放性製剤
SK143494A3 (en) Salts of peptides with carboxy-group terminated polyesters and method of their preparation
ZA200405852B (en) Polymer-based compositions for sustained release.
JP3765338B2 (ja) 注射用徐放性製剤の製造法
JPH10273447A (ja) 徐放性マイクロスフィア、その製造法および用途
KR100566573B1 (ko) Ｌｈｒｈ 동족체를 함유하는 서방성 미립구의 제조방법
KR101039237B1 (ko) 새로운 용출률이 개선된 서방출성 미립구의 제조방법
JP6238401B2 (ja) 生理活性ペプチド徐放性微粒子及びその製造方法

Legal Events

Date Code Title Description
AS Assignment

Owner name: PEPTRON CO., LTD., KOREA, REPUBLIC OF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEE, HEE-YONG;SHIN, EUN-HO;SEOL, EUN-YOUNG;AND OTHERS;REEL/FRAME:019225/0518

Effective date: 20070126

Owner name: DAEWOONG PHARMACEUTICAL CO., LTD., KOREA, REPUBLIC

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEE, HEE-YONG;SHIN, EUN-HO;SEOL, EUN-YOUNG;AND OTHERS;REEL/FRAME:020375/0027

Effective date: 20070126

AS Assignment

Owner name: DAEWOONG PHARMACEUTICAL CO., LTD., KOREA, REPUBLIC

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE SHOULD BE;ASSIGNORS:LEE, HEE-YONG;KIM, JUNG-SOO;SHIN, EUN-HO;AND OTHERS;REEL/FRAME:020743/0200

Effective date: 20070126

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION